Comparative Efficacy and Safety of Oral P2Y 12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: New randomized, controlled trials have become available on oral P2Y 12 inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-analysis of randomized controlled trials. Methods: We performed a network meta-analysis and direct pairwise comparison analysis of efficacy and safety outcomes from 12 randomized controlled trials including a total of 52 816 patients with acute coronary syndrome. Results: In comparison with clopidogrel, ticagrelor significantly reduced cardiovascular mortality (hazard ratio [HR], 0.82 [95% CI, 0.72–0.92]) and all-cause mortality (HR, 0.83 [95% CI, 0.75–0.92]), whereas there was no statistically significant mortality reduction with prasugrel (HR, 0.90 [95% CI, 0.80–1.01] and HR, 0.92 [95% CI, 0.84–1.02], respectively). In comparison with each other, there were no significant differences in mortality (HR prasugrel versus ticagrelor, 1.10 [95% CI, 0.94–1.29] and 1.12 [95% CI, 0.98–1.28]). In comparison with clopidogrel, prasugrel reduced myocardial infarction (HR, 0.81 [95% CI, 0.67–0.98]), whereas ticagrelor showed no risk reduction (HR, 0.97 [95% CI, 0.78–1.22]). Differences between prasugrel and ticagrelor were not statistically significant. Stent thrombosis risk was significantly reduced by both ticagrelor and prasugrel versus clopidogrel (28%–50% range of reduction). In comparison with clopidogrel, both prasugrel (HR, 1.26 [95% CI, 1.01–1.56]) and ticagrelor (HR, 1.27 [95% CI, 1.04–1.55]) significantly increased major bleeding. There were no significant differences between prasugrel and ticagrelor for all outcomes explored. Conclusions: Prasugrel and ticagrelor reduced ischemic events and increased bleeding in comparison with clopidogrel. A significant mortality reduction was observed with ticagrelor only. There was no efficacy and safety difference between prasugrel and ticagrelor. Registration: URL: https://www.crd.york.ac.uk/PROSPERO/ ; Unique identifier: CRD42019155648.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationHutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationTicagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117 · cited 1×
“…[NCT01294462] 12 mo NA Ticagrelor 90 mg bid 401 Japanese, Korean, and Taiwanese ACS patients with planned PCI Clopidogrel 75 mg od 400 [PLATO]9 Wallentin et al 2009 NEJM [NCT00391872] 12 mo October 2006 to July 2008 Ticagrelor 90 mg bid 9333 ACS with or without STEMI Clopidogrel 75 mg od…”
MethodSelf-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790 · cited 1×
“…mo June 27, 2008 to September 12, 2011 Prasugrel 10 mg od 4663 ACS without revascularization Clopidogrel 75 mg od 4663 [TRITON-TIMI 38]10 Wiviott et al 2007 NEJM [NCT00097591] 15 mo November 2004 to January 2007 Prasugrel 10 mg od 6813 ACS with scheduled PCI Clopidogrel 75 mg od…”
MethodPrasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874 · cited 2×
“Study Follow-Up Recruitment Period Arm (Maintenance Dose) No. of Patients (Intention to Treat) Study Setting Summary [The Elderly ACS II trial]21 Savonitto et al 2018 Circulation [NCT01777503] 12 mo November 15, 2012 to January 25, 2017 Prasugrel 5 mg od 713 Elderly ACS undergoing PCI Clopidogrel 75 mg od 730 [ISAR-RE…”
MethodInfluentialSelf-citationTicagrelor or prasugrel in patients with acute coronary syndromes
Schüpke, S., Neumann, F.-J., Menichelli, M., Mayer, K., Bernlochner, I., Wöhrle, J., Richardt, G., Liebetrau, C., Witzenbichler, B., Antoniucci, D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908973 · Cited by 816
Cited by
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo, D. A., Galli, M., Collet, J.-P., Kastrati, A., & O'Donoghue, M. O. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00904 · Cited by 299
Khan, S. U., Singh, M., Valavoor, S., Khan, M. U., Lone, A. N., Khan, M. Z., Khan, M. S., Mani, P., Kapadia, S. R., Michos, E. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046308 · Cited by 183
Self-citation
Metadata
- Authors
- Navarese, E. P., Khan, S. U., Kołodziejczak, M., Kubica, J., Buccheri, S., Cannon, C. P., Gurbel, P. A., De Servi, S., Budaj, A., Bartorelli, A., Trabattoni, D., Ohman, E. M., Wallentin, L., Roe, M. T., & James, S.
- Venue
- Circulation
- Published
- 2020-07-14
- Volume
- 142
- Issue
- 2
- Pages
- 150-160
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3031115393
- Cited by
- 146
- References
- 7
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.